EP 0979086 A2 20000216 - COMPOSITION FOR MODULATING AMYLOIDOSIS
Title (en)
COMPOSITION FOR MODULATING AMYLOIDOSIS
Title (de)
ZUSAMMENSTELLUNGEN ZUR MODULIERUNG VON AMYLOIDOSIS
Title (fr)
COMPOSITION DE MODULATION DE L'AMYLOIDOSE
Publication
Application
Priority
- US 9808463 W 19980428
- US 84761697 A 19970428
Abstract (en)
[origin: WO9848784A2] Methods for modulating amyloid deposition in a subject are described. An effective amount of at least one ATP binding cassette (ABC) transporter blocker is administered to a subject, such that modulation of amyloid deposition occurs. Methods also include administering an effective amount of at least one ABC transporter blocker, or a pharmaceutically acceptable salt thereof, to a subject such that a disease state associated with amyloidosis is treated. Packaged pharmaceutical compositions for treating amyloidosis are described. The package includes a container for holding an effective amount of a pharmaceutical composition and instructions for using the pharmaceutical composition for treatment of amyloidosis. The pharmaceutical composition includes at least one ABC blocker for modulating amyloid deposition in a subject. Methods for identifying agent which modulate amyloid deposition in a subject are also described. An effective amount of at least one ATP binding cassette (ABC) transporter blocker is administered to an organism, such that modulation of amyloid deposition occurs.
IPC 1-7
IPC 8 full level
A61K 45/00 (2006.01); A61K 31/138 (2006.01); A61K 31/277 (2006.01); A61K 31/352 (2006.01); A61K 31/4045 (2006.01); A61K 31/407 (2006.01); A61K 31/435 (2006.01); A61K 31/4433 (2006.01); A61K 31/46 (2006.01); A61K 31/47 (2006.01); A61K 31/473 (2006.01); A61K 31/475 (2006.01); A61K 31/49 (2006.01); A61K 31/5415 (2006.01); A61K 38/13 (2006.01); A61P 25/28 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP)
A61K 31/138 (2013.01); A61K 31/277 (2013.01); A61K 31/352 (2013.01); A61K 31/4045 (2013.01); A61K 31/407 (2013.01); A61K 31/46 (2013.01); A61K 31/473 (2013.01); A61K 31/475 (2013.01); A61K 31/49 (2013.01); A61K 31/5415 (2013.01); A61K 38/13 (2013.01); A61P 25/28 (2018.01); A61P 43/00 (2018.01)
Citation (examination)
- EP 0561597 A1 19930922 - INDENA SPA [IT]
- WO 9604915 A1 19960222 - EINSTEIN COLL MED [US], et al
- US 5466696 A 19951114 - WOOLF THOMAS F [US]
- Marin D.B. et al, Psychiatry Research, Vol. 58, (1995) "L-Deprenyl and physostigimine for the treatment of Alzheimer's disease", pp 181-189
- Asthana S. et al, Alzheimer Disease and Associated disorders, Vol. 9, No. 4 (1995) "Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine", pp 223-232
- Ueda K. et al, Brain Research, Vol. 748, (1997) "Chlorpromazine reduces toxicity and Ca2+ uptake induced by amyloid protein (25-35) in vitro", pp 184-188
- Scheinberg M.A. et al, Amyloid Amyloidosis Int. Symp. Amyloidosis, 6th 1991, Meeting date 1990, "Cyclosporin reduces the incidence of amyloid disease in casein treated mice", pp 874-882
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9848784 A2 19981105; WO 9848784 A3 19990812; AU 7260398 A 19981124; CA 2285948 A1 19981105; EP 0979086 A2 20000216; IL 132169 A0 20010319; JP 2002504895 A 20020212
DOCDB simple family (application)
US 9808463 W 19980428; AU 7260398 A 19980428; CA 2285948 A 19980428; EP 98919923 A 19980428; IL 13216998 A 19980428; JP 54725498 A 19980428